CN1234680C - 新的成像剂及其前体与制备方法 - Google Patents
新的成像剂及其前体与制备方法 Download PDFInfo
- Publication number
- CN1234680C CN1234680C CNB02122255XA CN02122255A CN1234680C CN 1234680 C CN1234680 C CN 1234680C CN B02122255X A CNB02122255X A CN B02122255XA CN 02122255 A CN02122255 A CN 02122255A CN 1234680 C CN1234680 C CN 1234680C
- Authority
- CN
- China
- Prior art keywords
- compound
- formula
- group
- compound according
- exists
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012216 imaging agent Substances 0.000 title description 8
- 238000002360 preparation method Methods 0.000 title description 6
- 239000002243 precursor Substances 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 94
- 238000000034 method Methods 0.000 claims abstract description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 125000006239 protecting group Chemical group 0.000 claims description 18
- -1 trifyl Chemical group 0.000 claims description 17
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 8
- 238000002603 single-photon emission computed tomography Methods 0.000 claims description 8
- DCERHCFNWRGHLK-UHFFFAOYSA-N C[Si](C)C Chemical group C[Si](C)C DCERHCFNWRGHLK-UHFFFAOYSA-N 0.000 claims description 7
- 125000001736 nosyl group Chemical group S(=O)(=O)(C1=CC=C([N+](=O)[O-])C=C1)* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 238000003384 imaging method Methods 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 210000004072 lung Anatomy 0.000 claims description 5
- 238000002600 positron emission tomography Methods 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- SIVPBAOGCHMZLZ-OBTQWQRRSA-N [18F]CCCN[C@@](CC1=CC=C(C=C1)O)(C(=O)O)C Chemical compound [18F]CCCN[C@@](CC1=CC=C(C=C1)O)(C(=O)O)C SIVPBAOGCHMZLZ-OBTQWQRRSA-N 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 210000003414 extremity Anatomy 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 239000000376 reactant Substances 0.000 claims 1
- 238000007794 visualization technique Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 6
- 206010006187 Breast cancer Diseases 0.000 description 5
- 208000026310 Breast neoplasm Diseases 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- VRYCUUXVTGQJDB-INIZCTEOSA-N methyl (2s)-3-(4-hydroxyphenyl)-2-methyl-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@](C)(C(=O)OC)CC1=CC=C(O)C=C1 VRYCUUXVTGQJDB-INIZCTEOSA-N 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- RQFUZUMFPRMVDX-UHFFFAOYSA-N 3-Bromo-1-propanol Chemical compound OCCCBr RQFUZUMFPRMVDX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000004700 cellular uptake Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- IQTRRURWJPEUOD-IBGZPJMESA-N methyl (2S)-3-(4-hydroxyphenyl)-2-[3-hydroxypropyl-[(2-methylpropan-2-yl)oxycarbonyloxy]amino]-2-methylpropanoate Chemical compound COC([C@@](N(OC(=O)OC(C)(C)C)CCCO)(CC1=CC=C(C=C1)O)C)=O IQTRRURWJPEUOD-IBGZPJMESA-N 0.000 description 2
- LFLNNIPIKXSTSP-SANMLTNESA-N methyl (2S)-3-(4-hydroxyphenyl)-2-methyl-2-[3-(4-methylphenyl)sulfonylpropyl-[(2-methylpropan-2-yl)oxycarbonyloxy]amino]propanoate Chemical compound COC([C@@](N(OC(=O)OC(C)(C)C)CCCS(=O)(=O)C1=CC=C(C)C=C1)(CC1=CC=C(C=C1)O)C)=O LFLNNIPIKXSTSP-SANMLTNESA-N 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 229960004441 tyrosine Drugs 0.000 description 2
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 description 1
- MDQGTXPQGZIAQD-JTQLQIEISA-N (2s)-2-(fluoroamino)-3-(4-hydroxyphenyl)-2-methylpropanoic acid Chemical compound FN[C@@](C(O)=O)(C)CC1=CC=C(O)C=C1 MDQGTXPQGZIAQD-JTQLQIEISA-N 0.000 description 1
- QZZYPHBVOQMBAT-LRAGLOQXSA-N (2s)-2-amino-3-[4-(2-fluoranylethoxy)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OCC[18F])C=C1 QZZYPHBVOQMBAT-LRAGLOQXSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100208721 Mus musculus Usp5 gene Proteins 0.000 description 1
- ROHFNLRQFUQHCH-MAWXAGFGSA-N N[C@@H](CC(C)C)[11C](=O)O Chemical compound N[C@@H](CC(C)C)[11C](=O)O ROHFNLRQFUQHCH-MAWXAGFGSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 description 1
- CDUUKBXTEOFITR-UHFFFAOYSA-N alpha-methylserine Natural products OCC([NH3+])(C)C([O-])=O CDUUKBXTEOFITR-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- 230000005250 beta ray Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000006115 defluorination reaction Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- ODCCJTMPMUFERV-UHFFFAOYSA-N ditert-butyl carbonate Chemical compound CC(C)(C)OC(=O)OC(C)(C)C ODCCJTMPMUFERV-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000007336 electrophilic substitution reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- WYJJUDJUEGRXHZ-NSHDSACASA-N methyl (2s)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoate Chemical compound COC(=O)[C@@](C)(N)CC1=CC=C(O)C=C1 WYJJUDJUEGRXHZ-NSHDSACASA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/872,156 US6824760B2 (en) | 2001-06-04 | 2001-06-04 | Imaging agents, precursors thereof and methods of manufacture |
| US09/872156 | 2001-06-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1401629A CN1401629A (zh) | 2003-03-12 |
| CN1234680C true CN1234680C (zh) | 2006-01-04 |
Family
ID=25358962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB02122255XA Expired - Fee Related CN1234680C (zh) | 2001-06-04 | 2002-06-04 | 新的成像剂及其前体与制备方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6824760B2 (enExample) |
| JP (1) | JP2003064046A (enExample) |
| KR (1) | KR100483650B1 (enExample) |
| CN (1) | CN1234680C (enExample) |
| TW (1) | TWI244925B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060115426A1 (en) * | 2004-08-11 | 2006-06-01 | Weichert Jamey P | Methods of detecting breast cancer, brain cancer, and pancreatic cancer |
| US8845999B2 (en) * | 2005-05-23 | 2014-09-30 | The Regents Of The University Of California | Tracers for monitoring the activity of sodium/glucose cotransporters in health and disease |
| EP2046686A1 (en) * | 2006-08-03 | 2009-04-15 | Hammersmith Imanet, Ltd | Fluoride drying method |
| WO2012025464A1 (en) | 2010-08-24 | 2012-03-01 | Bayer Pharma Aktiengesellschaft | Fluorodeuteriomethyl tyrosine derivatives |
| GB201021530D0 (en) * | 2010-12-20 | 2011-02-02 | Ge Healthcare Ltd | Purification of precursor compound by crystallisation |
| EP2520557A1 (en) * | 2011-05-03 | 2012-11-07 | Bayer Pharma Aktiengesellschaft | Novel precursors of glutamate derivatives |
| WO2015152128A1 (ja) * | 2014-03-31 | 2015-10-08 | 長瀬産業株式会社 | アミノ酸前駆体、アミノ酸およびその製造方法、ならびに該アミノ酸を用いたｐｅｔ診断用トレーサー |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3800302A1 (de) * | 1988-01-08 | 1989-07-27 | Kernforschungsanlage Juelich | Radiohalogentyrosinderivate, deren herstellung und verwendung |
-
2001
- 2001-06-04 US US09/872,156 patent/US6824760B2/en not_active Expired - Fee Related
-
2002
- 2002-06-03 JP JP2002161471A patent/JP2003064046A/ja active Pending
- 2002-06-04 TW TW091111997A patent/TWI244925B/zh not_active IP Right Cessation
- 2002-06-04 KR KR10-2002-0031228A patent/KR100483650B1/ko not_active Expired - Fee Related
- 2002-06-04 CN CNB02122255XA patent/CN1234680C/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6824760B2 (en) | 2004-11-30 |
| KR100483650B1 (ko) | 2005-04-18 |
| TWI244925B (en) | 2005-12-11 |
| CN1401629A (zh) | 2003-03-12 |
| US20030124059A1 (en) | 2003-07-03 |
| KR20020092818A (ko) | 2002-12-12 |
| JP2003064046A (ja) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101495924B1 (ko) | [ｆ-１８]-표지된 ｌ-글루탐산, [ｆ-１８]-표지된 ｌ-글루타민, 이들의 유도체 및 이들의 용도 및 이들의 제조 방법 | |
| JP5684333B2 (ja) | 放射性ハロゲン標識有機化合物の製造方法 | |
| CN115260160A (zh) | 一种靶向成纤维细胞活化蛋白fap的化合物及其制备方法和应用 | |
| RU2476423C2 (ru) | Способ получения радиоактивного, меченного фтором органического соединения | |
| CN1313436C (zh) | 肿瘤成像化合物 | |
| CN1921893A (zh) | 催化放射性氟化法 | |
| CN1234680C (zh) | 新的成像剂及其前体与制备方法 | |
| US10053423B2 (en) | Radioiodinated compounds | |
| CN1118160A (zh) | 作为放射保护剂的多胺衍生物 | |
| CN102558022A (zh) | 取代的异吲哚啉-1,3二酮衍生物 | |
| JP2007112725A (ja) | 無支持体の１８Ｆで標識したアミノ酸Ｏ−（２−［１８Ｆ］ｆｌｕｏｒｏｅｔｈｙｌ）−Ｌ−Ｔｙｒｏｓｉｎｅの製造方法。 | |
| CN117700479A (zh) | 靶向前列腺特异性膜抗原抑制剂、放射性标记物及其制备方法和应用 | |
| CN103221382B (zh) | 制备pet前体 | |
| CN102448931A (zh) | 蛋氨酸的放射标记的氟衍生物 | |
| RU2395489C2 (ru) | [f-18] меченная l-глютаминовая кислота, [f-18] меченный l-глютамин, их производные и их применение, а также способ их получения | |
| CN100340300C (zh) | 放射性过渡金属－亚氨杂二膦络合物、它们的制备以及其放射性药物组合物 | |
| Gomzina et al. | Methylation as a method for synthesis of radiopharmaceuticals for positron emission tomography | |
| KR102172407B1 (ko) | L-도파 전구체 화합물, 이의 제조방법, 및 이를 이용한 18f 표지 l-도파의 제조방법 | |
| CN1055930A (zh) | 6-取代的嘌呤基哌嗪衍生物的旋光异构体的制备方法 | |
| HK1082911B (en) | Radioactive transition metal-imido hetero-diphosphine complexes, their preparation and radiopharmaceutical compositions thereof | |
| CN1590391A (zh) | 二膦酸衍生物、99mTc标记的二膦酸衍生物及其应用 | |
| HK1069380A1 (en) | Regioselective synthesis of dtpa derivatives | |
| HK1069380B (en) | Regioselective synthesis of dtpa derivatives | |
| HK1043587A (en) | Regioselective synthesis of dtpa derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 Termination date: 20160604 |